AllAnalyst Report
logoMorningstarSeptember 11, 2020

Novartis AG: Trump's Executive Orders on Drug Prices Have Limited Impact on Our Industry FVEs and Moat Ratings

Symbols
NVS
Sector(s)
Healthcare
Rating
Premium
Current Price
$85.69
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total sales.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE